drugset / Trial / NCT05206318

Efficacy and Safety of Topical Cysteamine for Postinflammatory Hyperpigmentation

NCT05206318

RandomizedParallel-groupDouble-blindTreatment

Summary

Post-inflammatory hyperpigmentation is a common pigmentary skin disorder that is refractory to treatment. The treatment for postinflammatory hyperpigmentation is limited. Recent studies have shown that the topical skin care product cysteamine cream has a significant decrease in melanin index without obvious side effects in other dark spots such as melasma. The goal of this study is to determine the safety and efficacy of topical cysteamine in the treatment of post-inflammatory hyperpigmentation.

Timeline

Start
2021-12-10
Primary completion
2022-06-10
Completion
2022-12-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cysteamine Unknown Topical